L Cheng1, Tjada Schult1, Mara Lauer1, Yannick Berker2, Marcella Cardoso1, Lindsey Vandergrift1, Piet Habbel3, Johannes Nowak4, Martin Aryee1, Mari Mino-Kenudson1, and David Christiani5
1Mass General Hospital, Boston, MA, United States, 2German Cancer Research Center, Heidelberg, Germany, 3Charite Medical University, Berlin, Germany, 4Julius-Maximilians University, Wuerzburg, Germany, 5Harvard T.H. Chan School of Public Health, Boston, MA, United States
1Mass General Hospital, Boston, MA, United States, 2German Cancer Research Center, Heidelberg, Germany, 3Charite Medical University, Berlin, Germany, 4Julius-Maximilians University, Wuerzburg, Germany, 5Harvard T.H. Chan School of Public Health, Boston, MA, United States
Blood sera from lung
cancer patients prior to their diagnosis were studied with MRS to establish
LuCa screening metabolomic profiles that can triage patients to CT tests to
discover cancer earlier and reduce death rates.
Fig 2. Canonical scores calculated
with training cohort place testing cohort (Prior-to-Dx) between Healthy and
Time-of-Dx.
Fig 5. Testing and validation combination. a). Overall patient survival status with the M+SE
threshold (dashed line) calculated using all the Prior-to-Dx cases from both
cohorts. b). The Kaplan-Meier survival predictions for
all stage I and IIA cases. c).
Significant Kaplan-Meier
survival rates predicted using this threshold according to the date of patients
Time-of-Dx, with detailed statistical parameters listed.